Also trades as: 000028.SZ (SHZ) · $vol 9M
200028.SZ SHZ
China National Accord Medicines Corporation Ltd.
1W: +0.0%
1M: +0.6%
3M: +1.9%
YTD: -14.6%
1Y: -10.8%
3Y: -8.3%
5Y: -16.2%
HK$11.98 ($1.53)
+0.04 (+0.34%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$71.5B
-3.8% ▼
5Y CAGR: +3.7%
Gross Profit
$0
-100.0% ▼
Operating Income
$1.5B
+157.0% ▲
5Y CAGR: -7.4%
Net Income
$1.1B
+72.2% ▲
5Y CAGR: -4.6%
EPS (Diluted)
$1.99
+73.0% ▲
5Y CAGR: -4.6%
EBITDA
$1.5B
+39.5% ▲
5Y CAGR: -15.8%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $68.4B | $73.4B | $75.5B | $74.4B | $71.5B |
| YoY Growth | +14.6% | +7.4% | +2.8% | -1.5% | -3.8% |
| Cost of Revenue | $60.3B | $64.5B | $66.4B | $66.1B | $0 |
| Gross Profit | $8.0B | $8.9B | $9.1B | $8.2B | $0 |
| Gross Margin | 11.7% | 12.2% | 12.0% | 11.1% | 0.0% |
| R&D Expenses | $8M | $9M | $27M | $25M | $0 |
| SG&A Expenses | $4.9B | $5.5B | $2.8B | $2.7B | $0 |
| Operating Expenses | $5.9B | $6.5B | $6.6B | $7.7B | $70.0B |
| Operating Income | $2.0B | $2.3B | $2.5B | $573M | $1.5B |
| Operating Margin | 2.9% | 3.1% | 3.3% | 0.8% | 2.1% |
| Interest Expense | $288M | $262M | $248M | $258M | $0 |
| Income Before Tax | $2.0B | $2.3B | $2.5B | $575M | $1.5B |
| Tax Expense | $447M | $539M | $515M | $338M | $0 |
| Net Income | $1.3B | $1.5B | $1.6B | $642M | $1.1B |
| Net Margin | 2.0% | 2.0% | 2.1% | 0.9% | 1.5% |
| EPS (Diluted) | $2.40 | $3.47 | $2.87 | $1.15 | $1.99 |
| EBITDA | $3.5B | $3.9B | $4.1B | $2.4B | $1.5B |
| Shares Outstanding | 557M | 428M | 557M | 559M | 557M |